Everest Medicines Announces Partner Providence Reports Positive Top-Line Data from Phase 2 Primary Immunization Trial for mRNA COVID-19 Vaccine Candidate in Adults
- Written by PR Newswire
--Levels of neutralizing antibodies generated by PTX-COVID19-B were non-inferior to Comirnaty®----PTX-COVID19-B was well tolerated with no safety signals---- Everest is filing IND applications for phase 3 clinical trials for booster indication--
SHANGHAI, Oct. 19, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the...
